LGALS3 and prostate carcinoma: Previously, we demonstrated that TF-Ag mimicking and TF-Ag blocking inhibitors significantly reduce breast and prostate carcinoma metastasis in vivo by impeding the initial TF-Ag/Gal-3 mediated tumor cell adhesion to the endothelium [9, 19, 20].